Cingulate to Participate in Benzinga All Live Access Event

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) announced that its Chairman and CEO, Shane J. Schaffer, will speak at a live Benzinga All Access event on April 18, 2023, at 10 a.m. CST. The discussion will focus on unmet needs in attention deficit/hyperactivity disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. Schaffer will provide a company overview and recap recent clinical and business updates. The event will be available for viewing on Benzinga's YouTube channel and on Cingulate's website.

Cingulate is a biopharmaceutical company focused on developing next-generation pharmaceutical products aimed at improving treatment outcomes for patients with ADHD and potentially anxiety disorders through its PTR platform.

KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Tuesday April 18, 2023, at 10 a.m. CST.

The discussion will address the current unmet needs in attention deficit/hyperactivity disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area.

Dr. Schaffer will also provide a company overview and recap recent Cingulate clinical and business updates.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

About Cingulate^® 
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton 
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com 
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com 
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com 
201-723-5805

FAQ

What is Cingulate's participation in the Benzinga All Access event on April 18, 2023?

Cingulate's Chairman and CEO, Shane J. Schaffer, will discuss ADHD and the PTR platform's expansion into anxiety treatments.

Where can I watch the live Benzinga All Access event featuring Cingulate?

The event can be viewed live on Benzinga's YouTube channel and on Cingulate's website.

What topics will be covered by Cingulate's CEO at the event?

The discussion will cover unmet needs in ADHD and updates on Cingulate's clinical and business developments.

What is the significance of Cingulate's Precision Timed Release™ platform?

The PTR platform is designed to improve treatment outcomes for conditions like ADHD and anxiety.

What recent updates can we expect from Cingulate during the event?

Dr. Schaffer will provide a company overview and recap recent clinical and business updates.